Innovative drug, NVG-291, to undergo Phase II human clinical trials with spinal cord injuries in 2022

In a new development for those with a spinal cord injury, the NVG-291 treatment is set to undergo Phase II clinical trials in 2022. The drug will be put to the test for the first time in human volunteers, starting in the second half of this year, at the Shirley Ryan AbilityLab (SRA) in Chicago. The company behind the trials, NervGen, will not only be treating acute (newly-injured) patients in the trial but also chronic (longer length) patients, which are not normally included in such trials due to the extreme challenge their condition represents for any new drug. NVG-291 was designed to inhibit the mechanisms that prevent the body from repairing itself. Reducing these obstructive chemical signals makes it possible for “neuroplasticity” to take place in damaged neurons, which entails nerves rewiring existing connections and making new connections.

Details of when recruitment for the clinical trials will begin have not been released yet but you can read the entire article HERE.